Does the media prefer HBIO or QTRX?

In the previous week, Harvard Bioscience and Harvard Bioscience both had 1 articles in the media. Quanterix's average media sentiment score of 0.92 beat Harvard Bioscience's score of 0.00 indicating that Quanterix is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Harvard Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Quanterix 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings & valuation, HBIO or SEER?

Harvard Bioscience has higher revenue and earnings than Seer. Harvard Bioscience is trading at a lower price-to-earnings ratio than Seer, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Harvard Bioscience $87.81M 0.42 -$56.70M -$2.31 N/A Seer $16.58M 6.51 -$73.60M -$1.22 N/A

Is HBIO or SEER more profitable?

Harvard Bioscience has a net margin of -11.86% compared to Seer's net margin of -478.05%. Seer's return on equity of -27.23% beat Harvard Bioscience's return on equity. Company Net Margins Return on Equity Return on Assets Harvard Bioscience -11.86% -33.13% -4.80% Seer -478.05% -27.23% -23.99%

Does the media refer more to HBIO or SEER?

In the previous week, Seer had 2 more articles in the media than Harvard Bioscience. MarketBeat recorded 3 mentions for Seer and 1 mentions for Harvard Bioscience. Harvard Bioscience's average media sentiment score of 0.00 beat Seer's score of -0.13 indicating that Harvard Bioscience is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Harvard Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Seer 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer NAUT or HBIO?

In the previous week, Nautilus Biotechnology had 2 more articles in the media than Harvard Bioscience. MarketBeat recorded 3 mentions for Nautilus Biotechnology and 1 mentions for Harvard Bioscience. Nautilus Biotechnology's average media sentiment score of 0.00 equaled Harvard Bioscience'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nautilus Biotechnology 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Harvard Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor RPID or HBIO?

In the previous week, Rapid Micro Biosystems and Rapid Micro Biosystems both had 1 articles in the media. Harvard Bioscience's average media sentiment score of 0.00 beat Rapid Micro Biosystems' score of -0.50 indicating that Harvard Bioscience is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rapid Micro Biosystems 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative Harvard Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer CSBR or HBIO?

Harvard Bioscience has a consensus target price of $6.75, suggesting a potential downside of 15.84%. Given Harvard Bioscience's stronger consensus rating and higher possible upside, analysts plainly believe Harvard Bioscience is more favorable than Champions Oncology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Champions Oncology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Harvard Bioscience 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media prefer CSBR or HBIO?

In the previous week, Champions Oncology had 2 more articles in the media than Harvard Bioscience. MarketBeat recorded 3 mentions for Champions Oncology and 1 mentions for Harvard Bioscience. Champions Oncology's average media sentiment score of 0.71 beat Harvard Bioscience's score of 0.00 indicating that Champions Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Champions Oncology 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Harvard Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Harvard Bioscience (HBIO) Competitors

$8.02 +0.02 (+0.25%)

As of 09/4/2026 04:00 PM Eastern

Compare

HBIO vs. QTRX, SEER, NAUT, RPID, and CSBR

Should you buy Harvard Bioscience stock or one of its competitors? Harvard Bioscience's main competitors and comparable companies include Quanterix (QTRX), Seer (SEER), Nautilus Biotechnology (NAUT), Rapid Micro Biosystems (RPID), and Champions Oncology (CSBR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does Harvard Bioscience compare to Quanterix?

Harvard Bioscience (NASDAQ:HBIO) and Quanterix (NASDAQ:QTRX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, earnings, media sentiment, analyst recommendations, institutional ownership, profitability, valuation and risk.

80.9% of Harvard Bioscience shares are held by institutional investors. Comparatively, 86.5% of Quanterix shares are held by institutional investors. 17.0% of Harvard Bioscience shares are held by company insiders. Comparatively, 1.5% of Quanterix shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Harvard Bioscience presently has a consensus price target of $6.75, suggesting a potential downside of 15.84%. Quanterix has a consensus price target of $3.00, suggesting a potential upside of 11.52%. Given Quanterix's higher probable upside, analysts clearly believe Quanterix is more favorable than Harvard Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Harvard Bioscience	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Quanterix	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Harvard Bioscience has a net margin of -11.86% compared to Quanterix's net margin of -80.25%. Quanterix's return on equity of -26.09% beat Harvard Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Harvard Bioscience	-11.86%	-33.13%	-4.80%
Quanterix	-80.25%	-26.09%	-19.03%

In the previous week, Harvard Bioscience and Harvard Bioscience both had 1 articles in the media. Quanterix's average media sentiment score of 0.92 beat Harvard Bioscience's score of 0.00 indicating that Quanterix is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Harvard Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Quanterix	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Harvard Bioscience has higher earnings, but lower revenue than Quanterix. Harvard Bioscience is trading at a lower price-to-earnings ratio than Quanterix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Harvard Bioscience	$87.81M	0.42	-$56.70M	-$2.31	N/A
Quanterix	$138.90M	0.92	-$107.15M	-$2.63	N/A

Harvard Bioscience has a beta of 1.53, suggesting that its stock price is 53% more volatile than the broader market. Comparatively, Quanterix has a beta of 1.04, suggesting that its stock price is 4% more volatile than the broader market.

Summary

Harvard Bioscience beats Quanterix on 8 of the 15 factors compared between the two stocks.

How does Harvard Bioscience compare to Seer?

Harvard Bioscience (NASDAQ:HBIO) and Seer (NASDAQ:SEER) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, media sentiment, profitability, risk, earnings, analyst recommendations, dividends and valuation.

Harvard Bioscience has a beta of 1.53, meaning that its stock price is 53% more volatile than the broader market. Comparatively, Seer has a beta of 1.5, meaning that its stock price is 50% more volatile than the broader market.

80.9% of Harvard Bioscience shares are owned by institutional investors. Comparatively, 75.2% of Seer shares are owned by institutional investors. 17.0% of Harvard Bioscience shares are owned by company insiders. Comparatively, 11.3% of Seer shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Harvard Bioscience has higher revenue and earnings than Seer. Harvard Bioscience is trading at a lower price-to-earnings ratio than Seer, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Harvard Bioscience	$87.81M	0.42	-$56.70M	-$2.31	N/A
Seer	$16.58M	6.51	-$73.60M	-$1.22	N/A

In the previous week, Seer had 2 more articles in the media than Harvard Bioscience. MarketBeat recorded 3 mentions for Seer and 1 mentions for Harvard Bioscience. Harvard Bioscience's average media sentiment score of 0.00 beat Seer's score of -0.13 indicating that Harvard Bioscience is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Harvard Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Seer	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Harvard Bioscience presently has a consensus target price of $6.75, indicating a potential downside of 15.84%. Seer has a consensus target price of $4.00, indicating a potential upside of 105.13%. Given Seer's stronger consensus rating and higher probable upside, analysts clearly believe Seer is more favorable than Harvard Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Harvard Bioscience	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Seer	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	2 Strong Buy rating(s)	3.00

Harvard Bioscience has a net margin of -11.86% compared to Seer's net margin of -478.05%. Seer's return on equity of -27.23% beat Harvard Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Harvard Bioscience	-11.86%	-33.13%	-4.80%
Seer	-478.05%	-27.23%	-23.99%

Summary

Harvard Bioscience beats Seer on 9 of the 17 factors compared between the two stocks.

How does Harvard Bioscience compare to Nautilus Biotechnology?

Nautilus Biotechnology (NASDAQ:NAUT) and Harvard Bioscience (NASDAQ:HBIO) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, earnings, media sentiment and risk.

Nautilus Biotechnology has a beta of 0.87, meaning that its share price is 13% less volatile than the broader market. Comparatively, Harvard Bioscience has a beta of 1.53, meaning that its share price is 53% more volatile than the broader market.

Harvard Bioscience has higher revenue and earnings than Nautilus Biotechnology. Harvard Bioscience is trading at a lower price-to-earnings ratio than Nautilus Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nautilus Biotechnology	N/A	N/A	-$59M	-$0.45	N/A
Harvard Bioscience	$87.81M	0.42	-$56.70M	-$2.31	N/A

In the previous week, Nautilus Biotechnology had 2 more articles in the media than Harvard Bioscience. MarketBeat recorded 3 mentions for Nautilus Biotechnology and 1 mentions for Harvard Bioscience. Nautilus Biotechnology's average media sentiment score of 0.00 equaled Harvard Bioscience'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nautilus Biotechnology	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Harvard Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Nautilus Biotechnology currently has a consensus target price of $4.00, indicating a potential upside of 342.04%. Harvard Bioscience has a consensus target price of $6.75, indicating a potential downside of 15.84%. Given Nautilus Biotechnology's higher possible upside, equities research analysts clearly believe Nautilus Biotechnology is more favorable than Harvard Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nautilus Biotechnology	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Harvard Bioscience	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

50.7% of Nautilus Biotechnology shares are owned by institutional investors. Comparatively, 80.9% of Harvard Bioscience shares are owned by institutional investors. 41.1% of Nautilus Biotechnology shares are owned by company insiders. Comparatively, 17.0% of Harvard Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Nautilus Biotechnology has a net margin of 0.00% compared to Harvard Bioscience's net margin of -11.86%. Harvard Bioscience's return on equity of -33.13% beat Nautilus Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nautilus Biotechnology	N/A	-37.58%	-30.83%
Harvard Bioscience	-11.86%	-33.13%	-4.80%

Summary

Nautilus Biotechnology and Harvard Bioscience tied by winning 6 of the 12 factors compared between the two stocks.

How does Harvard Bioscience compare to Rapid Micro Biosystems?

Rapid Micro Biosystems (NASDAQ:RPID) and Harvard Bioscience (NASDAQ:HBIO) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, dividends, analyst recommendations, valuation, profitability, institutional ownership, risk and earnings.

Harvard Bioscience has a net margin of -11.86% compared to Rapid Micro Biosystems' net margin of -145.56%. Harvard Bioscience's return on equity of -33.13% beat Rapid Micro Biosystems' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rapid Micro Biosystems	-145.56%	-177.04%	-73.12%
Harvard Bioscience	-11.86%	-33.13%	-4.80%

Rapid Micro Biosystems presently has a consensus price target of $6.00, suggesting a potential upside of 358.02%. Harvard Bioscience has a consensus price target of $6.75, suggesting a potential downside of 15.84%. Given Rapid Micro Biosystems' stronger consensus rating and higher possible upside, research analysts clearly believe Rapid Micro Biosystems is more favorable than Harvard Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rapid Micro Biosystems	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Harvard Bioscience	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

52.6% of Rapid Micro Biosystems shares are held by institutional investors. Comparatively, 80.9% of Harvard Bioscience shares are held by institutional investors. 12.7% of Rapid Micro Biosystems shares are held by company insiders. Comparatively, 17.0% of Harvard Bioscience shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Rapid Micro Biosystems has a beta of 1.43, indicating that its share price is 43% more volatile than the broader market. Comparatively, Harvard Bioscience has a beta of 1.53, indicating that its share price is 53% more volatile than the broader market.

Rapid Micro Biosystems has higher earnings, but lower revenue than Harvard Bioscience. Harvard Bioscience is trading at a lower price-to-earnings ratio than Rapid Micro Biosystems, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rapid Micro Biosystems	$35.18M	1.87	-$47.12M	-$1.12	N/A
Harvard Bioscience	$87.81M	0.42	-$56.70M	-$2.31	N/A

In the previous week, Rapid Micro Biosystems and Rapid Micro Biosystems both had 1 articles in the media. Harvard Bioscience's average media sentiment score of 0.00 beat Rapid Micro Biosystems' score of -0.50 indicating that Harvard Bioscience is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rapid Micro Biosystems	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative
Harvard Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Harvard Bioscience beats Rapid Micro Biosystems on 8 of the 15 factors compared between the two stocks.

How does Harvard Bioscience compare to Champions Oncology?

Champions Oncology (NASDAQ:CSBR) and Harvard Bioscience (NASDAQ:HBIO) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, risk, media sentiment, institutional ownership, earnings and profitability.

Champions Oncology has a net margin of -1.87% compared to Harvard Bioscience's net margin of -11.86%. Champions Oncology's return on equity of -27.48% beat Harvard Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Champions Oncology	-1.87%	-27.48%	-3.84%
Harvard Bioscience	-11.86%	-33.13%	-4.80%

Champions Oncology has a beta of 0.4, indicating that its stock price is 60% less volatile than the broader market. Comparatively, Harvard Bioscience has a beta of 1.53, indicating that its stock price is 53% more volatile than the broader market.

Harvard Bioscience has a consensus target price of $6.75, suggesting a potential downside of 15.84%. Given Harvard Bioscience's stronger consensus rating and higher possible upside, analysts plainly believe Harvard Bioscience is more favorable than Champions Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Champions Oncology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Harvard Bioscience	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

41.3% of Champions Oncology shares are held by institutional investors. Comparatively, 80.9% of Harvard Bioscience shares are held by institutional investors. 47.0% of Champions Oncology shares are held by insiders. Comparatively, 17.0% of Harvard Bioscience shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Champions Oncology has higher earnings, but lower revenue than Harvard Bioscience. Champions Oncology is trading at a lower price-to-earnings ratio than Harvard Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Champions Oncology	$59.42M	1.22	-$1.17M	-$0.08	N/A
Harvard Bioscience	$87.81M	0.42	-$56.70M	-$2.31	N/A

In the previous week, Champions Oncology had 2 more articles in the media than Harvard Bioscience. MarketBeat recorded 3 mentions for Champions Oncology and 1 mentions for Harvard Bioscience. Champions Oncology's average media sentiment score of 0.71 beat Harvard Bioscience's score of 0.00 indicating that Champions Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Champions Oncology	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Harvard Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Champions Oncology beats Harvard Bioscience on 9 of the 16 factors compared between the two stocks.

Get Harvard Bioscience News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HBIO vs. The Competition

Export

Metric	Harvard Bioscience	Life Sciences Tools & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$36.51M	$9.94B	$7.25B	$12.91B
Dividend Yield	N/A	1.46%	2.53%	9.14%
P/E Ratio	-3.47	65.01	274.10	25.45
Price / Sales	0.42	111.84	687.94	125.94
Price / Cash	0.68	26.85	77.08	52.44
Price / Book	4.92	35.98	12.85	6.17
Net Income	-$56.70M	$56.67B	$3.49B	$350.08M
7 Day Performance	1.13%	-0.83%	1.04%	-0.14%
1 Month Performance	29.56%	4.01%	5.39%	0.94%
1 Year Performance	67.71%	24.29%	24.18%	14.02%

Harvard Bioscience Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HBIO Harvard Bioscience	0.7332 of 5 stars	$8.02 +0.3%	$6.75 -15.8%	+67.7%	$36.51M	$87.81M	N/A	490
QTRX Quanterix	1.3703 of 5 stars	$2.80 flat	$3.00 +7.1%	-40.9%	$132.41M	$138.90M	N/A	460	Positive News
SEER Seer	3.3559 of 5 stars	$2.05 +0.5%	$4.00 +95.1%	-7.1%	$113.51M	$16.58M	N/A	160	News Coverage
NAUT Nautilus Biotechnology	1.8701 of 5 stars	$0.88 +0.1%	$4.00 +356.6%	+36.9%	$111.48M	N/A	N/A	130	News Coverage
RPID Rapid Micro Biosystems	2.1917 of 5 stars	$1.65 -0.6%	$6.00 +263.6%	-51.8%	$82.76M	$35.18M	N/A	200	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:HBIO) was last updated on 9/6/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Harvard Bioscience (HBIO) Competitors

HBIO vs. QTRX, SEER, NAUT, RPID, and CSBR

How does Harvard Bioscience compare to Quanterix?

Summary

How does Harvard Bioscience compare to Seer?

Summary

How does Harvard Bioscience compare to Nautilus Biotechnology?

Summary

How does Harvard Bioscience compare to Rapid Micro Biosystems?

Summary

How does Harvard Bioscience compare to Champions Oncology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HBIO vs. The Competition

Harvard Bioscience Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Harvard Bioscience (HBIO) Competitors

HBIO vs. QTRX, SEER, NAUT, RPID, and CSBR

How does Harvard Bioscience compare to Quanterix?

Do insiders and institutionals hold more shares of HBIO or QTRX?

Do analysts rate HBIO or QTRX?

Is HBIO or QTRX more profitable?

Does the media prefer HBIO or QTRX?

Which has higher valuation and earnings, HBIO or QTRX?

Which has more risk and volatility, HBIO or QTRX?

Summary

How does Harvard Bioscience compare to Seer?

Which has more risk and volatility, HBIO or SEER?

Do institutionals and insiders believe in HBIO or SEER?

Which has preferable earnings & valuation, HBIO or SEER?

Does the media refer more to HBIO or SEER?

Do analysts recommend HBIO or SEER?

Is HBIO or SEER more profitable?

Summary

How does Harvard Bioscience compare to Nautilus Biotechnology?

Which has more volatility & risk, NAUT or HBIO?

Which has better earnings and valuation, NAUT or HBIO?

Does the media prefer NAUT or HBIO?

Do analysts prefer NAUT or HBIO?

Do insiders & institutionals believe in NAUT or HBIO?

Is NAUT or HBIO more profitable?

Summary

How does Harvard Bioscience compare to Rapid Micro Biosystems?

Is RPID or HBIO more profitable?

Do analysts prefer RPID or HBIO?

Do institutionals & insiders hold more shares of RPID or HBIO?

Which has more volatility and risk, RPID or HBIO?

Which has preferable earnings and valuation, RPID or HBIO?

Does the media favor RPID or HBIO?

Summary

How does Harvard Bioscience compare to Champions Oncology?

Is CSBR or HBIO more profitable?

Which has more volatility & risk, CSBR or HBIO?

Do analysts prefer CSBR or HBIO?

Do insiders & institutionals hold more shares of CSBR or HBIO?

Which has higher valuation and earnings, CSBR or HBIO?

Does the media prefer CSBR or HBIO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HBIO vs. The Competition

Harvard Bioscience Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools